Literature DB >> 8757014

Multiple cerebral lesions complicating therapy with interleukin-2.

B I Karp1, J C Yang, M Khorsand, R Wood, T C Merigan.   

Abstract

We reviewed the records and radiologic studies of eight patients who developed new focal neurologic abnormalities while receiving interleukin-2 (IL2)-based immunotherapy for malignancy or HIV infection. Initial confusion and delirium in the patients evolved into coma, ataxia, hemiparesis, seizures, and cortical syndromes including aphasia, apraxia, and cortical blindness. Imaging studies showed multiple white and gray matter lesions with a predilection for the occipital poles, centrum semiovale, and cerebellum. After cessation of IL2 treatment, seven patients improved to normal or near-normal neurologic function paralleled by resolution of the lesions on scans. One patient improved only minimally. Possible etiologies for the lesions include an IL2-induced cerebral vasculopathy, a direct toxic effect of IL2, or immunologically mediated damage.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757014     DOI: 10.1212/wnl.47.2.417

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Posterior Reversible Encephalopathy Syndrome: Local Experience From Saudi Arabia.

Authors:  Hussein Algahtani; Abdulhadi Algahtani; Ahmad Aldarmahi; Mohammed Hmoud; Yousef Marzuk; Bader Shirah
Journal:  Neurohospitalist       Date:  2016-08-31

2.  Granulocyte-stimulating factor filgrastim and molgramostim induced recurring encephalopathy and focal status epilepticus.

Authors:  O Kastrup; H C Diener
Journal:  J Neurol       Date:  1997-04       Impact factor: 4.849

3.  Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials.

Authors:  Aleksandra Wieczorek; Carla Manzitti; Alberto Garaventa; Juliet Gray; Vassilios Papadakis; Dominique Valteau-Couanet; Katarzyna Zachwieja; Ulrike Poetschger; Ingrid Pribill; Stefan Fiedler; Ruth Ladenstein; Holger N Lode
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575

4.  Yellow fever virus infection in Syrian golden hamsters: relationship between cytokine expression and pathologic changes.

Authors:  Guangyu Li; Tao Duan; Xiaoyan Wu; Robert B Tesh; Lynn Soong; Shu-Yuan Xiao
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

5.  Lysergic acid amide-induced posterior reversible encephalopathy syndrome with status epilepticus.

Authors:  Stephane Legriel; Fabrice Bruneel; Odile Spreux-Varoquaux; Aurelie Birenbaum; Marie Laure Chadenat; François Mignon; Nathalie Abbosh; Matthieu Henry-Lagarrigue; Laure Revault D'Allonnes; Pierre Guezennec; Gilles Troche; Jean Pierre Bedos
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

6.  Tacrolimus associated posterior reversible encephalopathy syndrome - a case series and review.

Authors:  Susmitha Apuri; Kristin Carlin; Edward Bass; Phuong Thuy Nguyen; John N Greene
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-02-18       Impact factor: 2.576

Review 7.  History and current state of immunotherapy in glioma and brain metastasis.

Authors:  Tresa McGranahan; Gordon Li; Seema Nagpal
Journal:  Ther Adv Med Oncol       Date:  2017-02-01       Impact factor: 8.168

Review 8.  Central Nervous System Complications in Children Receiving Chemotherapy or Hematopoietic Stem Cell Transplantation.

Authors:  Duccio Maria Cordelli; Riccardo Masetti; Daniele Zama; Francesco Toni; Ilaria Castelli; Emilia Ricci; Emilio Franzoni; Andrea Pession
Journal:  Front Pediatr       Date:  2017-05-15       Impact factor: 3.418

Review 9.  Hypothalamus-Pituitary-Adrenal Dysfunction in Cholestatic Liver Disease.

Authors:  Anca D Petrescu; Jessica Kain; Victoria Liere; Trace Heavener; Sharon DeMorrow
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-12       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.